Ipamorelin
Ipamorelin is a synthetic pentapeptide growth-hormone secretagogue that acts at the ghrelin receptor.
The short version
- Why people discuss it
- Discussed for sleep, exercise recovery and growth-hormone-related body-composition goals. Community interest does not establish benefit or a suitable treatment.
- What it is
- Ipamorelin is a synthetic pentapeptide growth-hormone secretagogue that acts at the ghrelin receptor.
- Biggest caution
- A short-term growth-hormone response is not evidence of improved recovery, body composition or sleep. Community-product identity, sterility and long-term human safety are not established.
- Stack context
- Related profiles reflect adjacent community topics or biological context. They do not establish combination benefit, compatibility or a validated regimen.
Dose and frequency reference
Reference only — not a recommendation. Amounts describe source-specific community examples, selected study regimens or the named product label. They do not establish safety, effectiveness, product identity, or a suitable dose for any person. Never convert mg, mcg, or IU into syringe “units” without the exact product concentration.
Sources report different amounts or schedules; the reference below is a named example, not a consensus.
Subcutaneous injection
Community reference · Not clinical guidance- Amount
- 100–200 mcg per administration
- Frequency
- Once or twice daily
- Duration / phase
- 8–12 weeks
Source-described standard range. Older 200–300 mcg and 12–16-week conventions are higher/longer variants; this is not established human subcutaneous dose-finding. Reference only; this does not establish safety, effectiveness or individual suitability.
Community source · reviewed 2026-09-27Compare reported schedules
Saved source material reviewed 2026-09-27. Multiple pages from one publisher count as one source family; agreement does not establish what most people use. SC means subcutaneous; IM intramuscular; IP intraperitoneal.
- PeptideDosages — saved source reviewed September 27, 2026
100→250 mcg SC once nightly, 8–12 weeks, optional 16.
- Peptidepedia — saved source reviewed September 27, 2026
100–200 mcg 1–2 times/day, 8–12 weeks; advanced 200 mcg 2–3 times/day; FAQ also says 12–16 weeks.
Evidence & sources · Community source profile
AxonRep synthesizes community discussion signals from its internal research corpus. Individual creator sources remain attributed to the synthesis; public reference sites used in the latest comparison are linked separately. The synthesis is not clinical evidence.
- AxonRep community research synthesisAxonRep synthesis · Checked 2026-09-12
- PeptideDosages — saved source reviewed September 27, 2026Community reference · Checked 2026-09-27
- Peptidepedia — saved source reviewed September 27, 2026Community reference · Checked 2026-09-27